Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Natco Settles Over Canadian Revlimid Rival

Deal Comes After Indian Firm Reports Falling Sales Last Year

Executive Summary

India’s Natco has struck a deal with Celgene to settle litigation over its proposed generic lenalidomide rival to Revlimid in Canada. News of the settlement came shortly after the Indian firm reported a decline in quarterly and annual revenues following supply chain disruptions caused by the coronavirus crisis.

You may also be interested in...



Revlimid Rivals Debut In Canada

Dr Reddy’s and Natco have announced launches of Canadian rivals to Celgene’s Revlimid, with lenalidomide capsules from both companies made available from the start of September following settlements with the originator.

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.  

India’s IPA Sees No Imminent Coronavirus Shortages

The Indian Pharmaceutical Alliance is working closely with the World Health Organization and International Generic and Biosimilar Medicines Association, as well as regional off-patent industry bodies in the US and Europe, to “navigate challenges on the manufacturing and logistics front” due to the coronavirus pandemic. Meanwhile, the IPA has welcomed domestic initiatives to boost API manufacturing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel